

# Evaluation of them against DLA and EAC Bearing Mice

Somayeh Afsah Vakili<sup>1</sup>

<sup>1</sup> Visveswarapura Institute of Pharmaceutical Sciences,

*Received: 7 December 2016 Accepted: 4 January 2017 Published: 15 January 2017*

## Abstract

In spite of the fact that substantial advancement have been made in the remedy and control of cancer progression, remarkable inadequacy for improvement remain. Natural therapy can diminish adverse effect of chemotherapy. Currently over 60

**Index terms**— honey bee venom, zingiber officinale roscoe, cytotoxic potency, human breast adenocarcinoma cells.

## 1 I. Introduction

ne of the governing causes of global mortality is cancer (Lopez et al., 2006). World Health Organization (WHO) reported that there were 8.2 million deaths in 2012 and it is estimated up to 13.1 million deaths in 2030 (Ferlay et al., 2008). In the United States, one in four deaths is ascribed to cancer (Jemal et al., 2007). Cancer cells are susceptible to chemotherapy by reason of losing normal function and uncontrolled proliferating of cells. Nevertheless, some of the anticancer drugs have carcinogenicity themselves such as alkylating agents and anthracycline antibiotics (Sharma and Sharma, 2007). Natural products have tremendous potential to issue newest medicines since their natural chemicals may supply chemoprotective potential versus cancer. Bee venom contains major components that include histamine catecholamines, polyamines, melittin, and phospholipase A2. Melittin represents about 50-70% of all antimicrobial peptides present in bee venom. Some antimicrobial peptides isolated from insects display a wide range of biological activities including melittin, cecropin related peptides and the magainins which have been shown to exhibit antitumor activity for cells derived from mammalian and human tumours. It is also one of the most potent inhibitors of calmodulin activity and a potent inhibitor of cell growth and clonogenicity (Orsolic et al., 2009). Zingiber officinale Roscoe belongs to family Zingiberaceae commonly called as ginger (Radhakrishnan, 2014). Ginger contains the volatile compounds such as alpha-zingiberene, betasessquiphellandrene, alpha-farnesene, beta-bisabolene, alpha-curcumene, which are mostly consisted of sesquiterpene hydrocarbons and the non-volatile pungent compounds are mainly oleoresin (gingerol, shogaol), phenol (zingerone, gingeol). Ginger also possesses anthelmintic, anti-bacterial and anti-viral activities. Moreover, ginger was found to be active against inflammatory, allergic, degenerative, cardiovascular and metabolic disorders and anticancer activity (Poltronieri et al., 2014). The current investigation was undertaken to anticipate the anticancer potential of combination of honey bee venom and ethanol extract of Zingiber officinale Roscoe.

## 2 II. Materials and Methods

### 3 a) Plant material and Preparation of extract

The rhizomes of Zingiber officinale Roscoe (Zingiberaceae) were collected from Mysore District, Karnataka State, India and authenticated by Green

In Vitro Cytotoxic Screening of Combination of Honey Bee Venom and Ethanol Extract of Zingiberaceae and in Vivo Anticancer Evaluation of them against DLA and EAC Bearing Mice Chem of India, Bangalore, Karnataka, India; a voucher specimen (MZO-GR-101) was conserved for future references. The rhizomes were dried and converted into fine powder using an electrical blender. Fine powder (100 g) was homogenized in ethanol (95%; 500 mL) and left in a conical flask at room temperature for 3 days. The mixture was filtered through a fine muslin cloth and a filter paper (Whatman No. 1). The extract became concentrated by using the Eyela rotary evaporator. The percentage yield of ethanol extract of Zingiber officinale Roscoe was 12%.

#### 4 b) Bee venom

Lyophilized whole bee venom was purchased from New Technique Laboratory Ltd (Georgia). Bee venom was reconstituted in distilled water to obtain the desirable concentrations for invitro and invivo study and centrifuged at 12,000 rpm for 10 minutes to remove insoluble materials.

#### 5 c) Chemicals d) Cell lines

Human breast adenocarcinoma cells (MCF-7), Normal V79 cells (Chinese hamster lung fibroblast) and HEp-2 (Human epithelial carcinoma) cells procured from National centre for cell sciences, NCCS Pune, India. The cell lines were grown in 25 cm<sup>2</sup> tissue culture flasks containing Minimum essential media (MEM media) with 10% fetal Bovine Serum (FBS), 1% L-glutamine and 50 µg/ml gentamycin sulphate at 37°C in CO<sub>2</sub> incubator in an atmosphere of humidified 5% CO<sub>2</sub> and 95% air. The cells were maintained by routine sub culturing in 25cm<sup>2</sup> tissue culture flasks twice a week. Ehrlich ascites carcinoma cells (EAC) and Dalton's ascites lymphoma cells (DLA) were obtained by Amala Cancer Research Center, Thrissur, Kerala, India and were maintained by weekly intraperitoneal (i.p) inoculation of 10<sup>6</sup> cells/mouse in the laboratory. Both the cell lines maintained in the peritoneal cavity of Swiss albino mice were collected from an animal having 7 days old ascitic tumour by aspirating the ascetic fluid in sterile isotonic saline. The viable EAC/DLA cells were counted (Trypan blue indicator) under microscope. A fixed number of viable cells 10<sup>6</sup> cells were inoculated into the peritoneal cavity of each recipient mouse.

#### 6 e) Animals

The experiments were done on 8-10 weeks old Swiss albino mice of either sex weighing 25-35 gm were procured from a registered breeder in Viveswarapura Institute of Pharmaceutical Sciences. Animals were maintained under controlled conditions of temperature (25 ± 3 °C) and humidity (50 ± 5 %) and were caged in sterile polypropylene cages containing sterile paddy husk. The study protocol was authorized by Institutional Animal Ethics Committee (IAEC), Visveswarapura Institute of Pharmaceutical Sciences, Bangalore. (Registration No: 152/1999, renewed in 2012).

#### 7 f) Cytotoxic screening

i. Sulforhodamine B colorimetric assay for cytotoxic screening The monolayer cell culture of HEp-2 (Human epithelial carcinoma) was trypsinized and the cell count adjusted to 1.0 x 10<sup>5</sup> cell/ml using medium (MEM) supplemented with 10% FBS. To each well of the 96 well microplate, 1x10<sup>4</sup> cells in a volume of 0.1ml was added and incubated for 24 h in CO<sub>2</sub> incubator for cell adherence. After 24 h, cells were treated with combination of honey bee venom (5.7 µg/ml) and ethanol extract of Zingiber officinale Roscoe (100 µg/ml) in a volume of 100 µl. The plates were then incubated at 37°C for 3 days in 5% CO<sub>2</sub> atmosphere, and microscopic examination was carried out and observations recorded every 24 h. After 72 h incubation, cell monolayers were fixed with 10% (w/v) trichloroacetic acid and stained for 30 min, after which the excess dye was removed by washing repeatedly with 1% (v/v) acetic acid. The air-dried plates were stained with 100 µl of 0.4% Sulforhodamine B solution (SRB) (0.4 g of SRB was dissolved in 100ml of 10 mM Tris base solution) for 30 min. The unbound dye was then removed by rapidly washing four times with 1% acetic acid. The plates were shaken vigorously for 5 min. The absorbance was measured using micro plate reader at a wavelength of 510 nm (Orellana and Kasinski, 2016).

The percentage growth inhibition was calculated using the formula below: % Growth inhibition =  $100 \times \frac{(T - T_0)}{(C - T_0)}$

T is the OD after exposure to certain concentration of drugs, T<sub>0</sub> is the OD at the start of drug exposure and C is the OD of untreated group which served as control.

ii

#### 8 . Trypan blue dye exclusion method

The combination of honey bee venom (20 µg) and ethanol extract of Zingiber officinale Roscoe (500 µg) was used for the preparation of the stock solution (520 µg/ml) in Phosphate buffered saline. Serial dilutions (25µg/ml, 50µg/ml, 75µg/ml, 100µg/ml of sample solution) were prepared in PBS. The amount of 200µl of sample solutions were poured in tubes and made up to 800 µl with PBS (Phosphate buffered saline). 100µl of EAC with a concentration of 10<sup>6</sup> cells/ml of Phosphate buffered Saline was added to the tubes. Solvent alone was served as control. 100 µl of trypan blue was added to all test tubes after 3 hours incubation. Ascetic tumour cells were counted by Cell Counting machine (Cedex, Roche). The percentage of cytotoxicity (% dead cells) was calculated using the formula (Saluja et al., 2011)

## 9 : % Cytotoxicity= (Total cells counted-total viable cells) / Total cells counted×100 iii. Brine shrimp lethality (BSL) bioassay

The brine shrimp (*Artemia salina*) eggs were supplied from Brine Shrimp Direct, Ogaden, UT, USA. The tested chamber was partitioned into two equal parts with aeration supply. One part was lighted up with a bulb (60 W), while the other was darkened. Brine shrimp eggs were placed in the dark side and incubated at room temperature for 48h. The nauplii were moved towards the illuminated side after hatching, where they were collected by a Pasteur pipette. The tested sample were prepared by dissolving the combination of honey bee venom (0.26 mg) and ethanol extract of *Zingiber officinale* Roscoe (4.74 mg) in 5ml of DMSO to obtain 500 ppm stock solution and then diluted with sea water to get the requisite concentration (20, 50, 75, 100, 200 and 300 µg/ml). 5-Flourouracil (5-FU) was used as standard (10, 25, 50 and 75 µg/ml). Ten shrimps were transferred in each vial and made up of volume to 5ml with sea water. A drop of dry yeast suspension (3mg in 5ml sea water) was poured to each vial as food. Control vials were provided by adding equal volumes of distilled water. The vials were sustained under illumination. Survivors were counted by using 3 × magnifying glasses after 24h and the percentage of deaths (% Mortality) and IC 50 value were calculated by using Finney Computer program (Meyer et al., 1982).

iv. MTT assay Cells were subcultured in 96-well plates at a density of 10<sup>3</sup> cells per well with combination of honey bee venom (5.7 µg/ml) and ethanol extract of *Zingiber officinale* Roscoe extract (100 µg/ml) and cisplatin as standard (2.5 µg/ml) for 48 h in a final volume of 100 µl of media. Then, the medium was removed and 10 µL of MTT (5 mg/mL in PBS) was added to the fresh medium. After 4 h incubation at 37 °C, 100 µL DMSO was added to each well and plates were agitated for 1 min. The optical density (OD) was read using a conventional ELISA plate reader at 570nm. The percentage of viability was calculated as the following formula (Lai et al., 2012): (Viable cells)%=(OD of drug-treated sample/OD of untreated sample)×100

## 10 g) Treatment designed

For EAC/ DLA evaluation, Healthy, adult Swiss albino mice were divided into 6 groups consisting of 6 animals in each group. In EAC study, all the animals in each group, excluding group 1 received 10<sup>6</sup> EAC cells/mouse i.p. Group 1 considered as normal and group 2 was EAC control. Group 3 was administrated by standard drug cisplatin 3.5 mg/kg b.w, i.p, group 4, 5 and 6 were administered, orally with formulation of F 1 (honey bee venom (10 mg/kg) and ethanol extract of *Zingiber officinale* Roscoe extract (100 mg/kg), F 2 (honey bee venom (25 mg/kg) and ethanol extract of *Zingiber officinale* Roscoe extract (150 mg/kg) and F 3 (honey bee venom (50 mg/kg) and ethanol extract of *Zingiber officinale* Roscoe extract (200 mg/kg), respectively for 10 consecutive days. For DLA investigation, Group 1 served as normal control, group 2 was DLA control. Group 3 received standard drug cisplatin 3.5 mg/kg b.w, i.p, group 4, 5 and 6 were administered, orally with formulation of F 1 , F 2 and F 3 respectively for 10 days.

## 11 h) Determination of survival time

At termination surviving animals of EAC/DLA tumour bearing mice were counted and the Mean survival time (MST) and the % increase in life span (% ILS) were calculated by the formula (Durairaj et al., 2009).

## 12 % ILS = (

MST of treated group / MST of the control group × 100 i) Body Weight Analysis All mice were weighed on the day of tumour inoculation and the weekly intervals. Average gain in body weight and % increase in body weight was calculated by the formula 1 for EAC tumour bearing mice by and % reduction in body weight was calculated by formula 2 for DLA tumour bearing mice (Durairaj et al., 2009). Formula 1: [% increase in body weight = (animal bw on resp. day/animal bw on day 0)-1 × 100] Formula 2: [% reduction in body weight= (Gain in bw of control-gain in bw in treated gp/ gain in bw of control) × 100]

## 13 j) Hematological parameters

At the end of evaluation, on day 11, mice were anaesthetized by is oflurane. blood was collected from retro-orbital of mice for reckoning of white blood cell (WBC) count, red blood cells (RBC) count and the hemoglobin (Hb) content by standard procedures (Jain, 2005).

## 14 k) Statistical analysis

The data were manifested as mean ± S.E.M. The results were statistically analyzed by means analysis of variance (ANOVA) followed by Dunnett's post hoc test where the difference was contemplated significant if p < 0.05.

## 18 II. EFFECT OF COMBINATION OF HONEY BEE VENOM AND ETHANOL EXTRACT OF ZINGIBER OFFICINALE ROSCOE ON TUMOUR VOLUME IN DLA/ EAC TUMOUR BEARING MICE

### 15 III. Results

#### 16 a) In vitro cytotoxic screening

148 In SRB assay, combination of honey bee venom (5.7 ?g/ml) and ethanol extract of Zingiber officinale Roscoe (100  
149 ?g/ml) displayed good cell growth inhibition with IC 50 value of 53 µg/ml. In trypan blue dye exclusion assay,  
150 the mentioned formulation caused mortalities effectively with IC 50 value of 37.49 µg/ml. In BSL assay, the  
151 combination of honey bee venom (0.26 mg) and ethanol extract of Zingiber officinale Roscoe (4.74 mg) exhibited  
152 mortality of cells with IC 50 value of 48.31 µg/ml. The combination of honey bee venom (5.7 ?g/ml) and  
153 ethanol extract of Zingiber officinale Roscoe extract (100 ?g/ml) was examined on normal Chinese hamster lung  
154 fibroblast cells (V79) and human breast adenocarcinoma cells (MCF-7) by MTT assay to assess its selectivity  
155 towards normal and cancer cells. On normal cells, V79, the IC 50 of formulation and cisplatin as standard was  
156 found to be 89.61 µg/ml and 6.43 µg/ml respectively with 77% of cell survival for formulation. On MCF-7, the  
157 IC 50 of formulation and cisplatin as standard was found to be 66.52 µg/ml and 1.91 µg/ml respectively with  
158 61% of cell survival for formulation. So it means the combination of honey bee venom (5.7 ?g/ml) and ethanol  
159 extract of Zingiber officinale Roscoe extract (100?g/ml) exhibited more cytotoxic activity towards cancer cells.

#### 17 b) In vivo anticancer study i. Effect of combination of honey bee venom and ethanol extract of Zingiber officinale Roscoe on body weight in DLA/ EAC tumour bearing mice

163 Figure 1 exhibits the percentage reduction in the body weight after treatment with of combination of honey  
164 bee venom and ethanol extract of Zingiber officinale Roscoe on body weight in DLA tumour bearing mice. The  
165 percentage reduction in body weight of DLA tumour bearing mice was found to be 65.38 % in the group treated  
166 with cisplatin. Maximum percentage reduction in body weight was found to be 55.21% in the group treated  
167 with F 3 formulation. Figure ?? displays the percentage increase in the body weight after treatment with of  
168 combination of honey bee venom and ethanol extract of Zingiber officinale Roscoe on body weight in EAC tumour  
169 bearing mice. Substantial rise in body weight was perceived in EAC control mice with a maximum gain ( $20.85 \pm$   
170  $0.41$  %). Standard cisplatin and all herbal formulation treatment significantly declined the elevated body weight,  
171 hence the percentage increase in body weight was found to 3.68% and 4.61% in group treated with cisplatin and  
172 F 3 formulation respectively.

#### 18 ii. Effect of combination of honey bee venom and ethanol extract of Zingiber officinale Roscoe on tumour volume in DLA/ EAC tumour bearing mice

176 Figure ?? shows the effect of combination of honey bee venom and ethanol extract of Zingiber officinale Roscoe  
177 on tumour volume in DLA tumour bearing mice. The DLA inoculation increased the tumour volume ( $0.82 \text{ cm}^3$ )  
178 in mice. The cisplatin treated group significantly ( $\alpha < 0.05$ ) exhibited maximum reduction in tumour volume  
179 ( $0.22 \text{ cm}^3$ ) in mice. F 3 formulation treated group has shown very effective in diminishing tumour volume to  
180  $0.29 \text{ cm}^3$  when compared with DLA control. Table 1 manifests the effect of combination of honey bee venom and  
181 ethanol extract of Zingiber officinale Roscoe on tumour volume in EAC tumour bearing mice. F 3 formulation  
182 treated group significantly ( $r < 0.001$ ) decreased the tumour volume as compared to the EAC control group. iii.  
183 Effect of combination of honey bee venom and ethanol extract of Zingiber officinale Roscoe on mean survival  
184 time and percentage increase in life span in DLA/ EAC tumour bearing mice Table 2 indicates the Effect of  
185 combination of honey bee venom and ethanol extract of Zingiber officinale Roscoe on mean survival time and  
186 percentage increase in life span in DLA tumour bearing mice. In DLA control group, the mean survival time  
187 was 20 days and it rose significantly up to 32 and 28 days with remedy by standard cisplatin group and F 3  
188 formulation group respectively. The % ILS was observed to be 55.64% and 39.89% in DLA induced mice treated  
189 with standard cisplatin group and F 3 formulation group respectively. Table 3 revealed the Effect of combination  
190 of honey bee venom and ethanol extract of Zingiber officinale Roscoe on mean survival time and percentage  
191 increase in life span in DLA tumour bearing mice. The mean survival time in cisplatin treated mice found to be  
192 25 days ( $\alpha < 0.05$ ). As compared to the EAC control group, F 3 formulation treated group has shown significant  
193 ( $\alpha < 0.05$ ) increase in the life span than the rest of the groups. 4 presents the Effect of combination of honey bee  
194 venom and ethanol extract of Zingiber officinale Roscoe on hematological parameters in DLA tumour bearing  
195 mice. The total WBC count found significantly increased in DLA control group when compared with the normal  
196 group ( $c < 0.001$ ). F 1 , F 2 and F 3 formulations exhibited activity at per with cisplatin as standard and these  
197 differences were statistically nonsignificant for F 3 formulations treated group and  $y < 0.01$ ,  $z < 0.001$  for F 2 and  
198 F 1 formulations treated group respectively. RBC count and Hb count in DLA groups were significantly ( $c <$   
199  $0.001$ ) diminished as compared to normal group. Treatment with F 3 formulations revealed superior ascend in  
200 RBC count and Hb count when compared with DLA control group and restored these values towards normal.  
201 Treatment with the all three formulation significantly rose the RBC level and Hb content when compared to the  
202 EAC control [Figure ??,5]. F 3 formulation indicated better effect than other combinations as compared with

---

EAC control ( $b < 0.05$ ). The WBC count has been reduced significantly when compared with the EAC bearing mice and restored more towards the normal level with remedying by all three formulations. F 3 formulation displayed better activity when compared to the rest of the evaluated formulation and the cisplatin ( $c < 0.05$ ) [Figure ??].

## 19 Volume XVII Issue II Version I

## 20 Discussion

The use of natural products to control or seize the carcinogenic activity issues an alternative to the use of typical allopathic remedy for therapy of the ailment (Balachandran and Govindarajan, 2005). Natural sources have been investigated in clinical researches and are being evaluated to comprehend their cancericidal properties against varied cancers (Balachandran and Govindarajan, 2005). Inevitably, this topical investigation was endeavoured to predict anticancer potential of combination of honey bee venom and ethanol extract of *Zingiber officinale* Roscoe against different cell lines. The cytotoxic screening of combination of honey bee venom and ethanol extract of *Zingiber officinale* Roscoe revealed the beneficial effect against cancer cell lines for invitro studies. Cytotoxic of anticancer drugs towards the normal cells are crucial problems in cancer remedy and engender the risk of promoting secondary malignancy (Shi et al., 2008). There has been a concerted research in the current years for the discovery of novel selective anticancer agents which show more cytotoxic activity towards cancer cells than normal cells. Therefore, in the present investigation of the cytotoxicity of combination of honey bee venom and ethanol extract of *Zingiber officinale* Roscoe on cancer (MCF-7) and normal (V79) cells was determined to check their selectivity that indicated more cytotoxic activity towards cancer cells with 61% of cell survival for formulation. In ascites /solid tumour models, a considerable rise in body weight of the animals was perceived in EAC/DLA control mice due to progressive accumulation of ascites tumour cells and rapid solid tumour growth respectively. The trustworthy criterion for determining the potential of any anticancer drugs is the extension of life span of animal (Dai and Mumper, 2010). The present study showed F 3 combination of honey bee venom and ethanol extract of *Zingiber officinale* Roscoe significantly ascended the life span in both EAC/DLA models. Additionally, the diminished volume of tumor and extended survival time of mice recommend the retarding effect of formula on cell division (Ames et al., 1993). Pivotal erythrocytopenia and anemia in cancer patients is mostly due to myelosuppression during chemotherapy (Mondal et al., 2014). Results acquired from investigation evinced F 3 combination of honey bee venom and ethanol extract of *Zingiber officinale* Roscoe reestablished the hematological parameters so it can alleviate erythrocytopenia and anemia in cancer patients. The prior phytochemical evaluation of honey bee venom has disclosed the presence of melittin which has antitumour activity (Orsolic et al., 2009). It is also one of the most potent inhibitors of calmodulin activity and a potent inhibitor of cell proliferation and clonogenicity. Calmodulin is vital for numerous processes that are crucial for normal cellular function, including the assembly and disassembly of microtubules, calcium extrusion from cells by a calciummagnesium, ATPase, and the activation of many intracellular enzymes, such as phosphatases, protein kinases and cyclic nucleotide phosphodiesterase. Through interfering with any of these known functions, calmodulin inhibitors would be potentially toxic to cells. The evidence advocates that calmodulin inhibitors are cytotoxic to malignant cells (in both invitro and invivo investigation) which can postulated by either of following mechanisms: 1-Interfering with cell cycle by and block the movement of chromosome during metaphase that leads to inhibit the DNA synthesis, 2-Apoptosis and lysis of tumour cells (Orsolic et al., 2009). The previous phytochemical analysis has divulged the presence of ??[6] gingerol as the non-volatile pungent compounds in *Zingiber officinale* Roscoe (Poltronieri et al., 2014). ??[6] gingerol demonstrated antioxidant activity by modifying the redox status through inhibition of RNS (particularly peroxynitrite) (Radhakrishnan et al., 2014) and also inhibited the COX-2 expression by reason of blocking of P38 MAP kinase and NF-Kappa B (NF  $\kappa$  B) signalling pathway (Kim et al., 2005). There is ample evidence that COX-2 is overexpressed in about 85% of cancers. COX-2 is prostaglandin-endoperoxide synthase enzyme which catalyses the conversion of arachidonic acid to prostaglandin such as PGE2. PGE2 cause to increase the level of VEGF (Vascular endothelial growth factor) which lead to angiogenesis of cancer cells. It increases the level of AKt which enhances transcription factor of anti apoptosis in nucleus, additionally, it ascends the level of Bcl-2 which is an anti-apoptotic agent and hence it prevents the apoptosis process in cancer cells which causes to mortality of them. It means COX-2 inhibitor can induce apoptosis as well as anti-angiogenesis (Sharma and Sharma, 2007). Zingerone is another the non-volatile pungent compounds with phenolic nature in *Zingiber officinale* Roscoe (Poltronieri et al., 2014). The data obtained from literature revealed that zingerone also has antioxidant activity against peroxynitrite and superoxide anion (Radhakrishnan et al., 2014).

## 21 V. Conclusion

Ergo, based on the current investigation, pharmacological potential of honey bee venom and ethanol extract of *Zingiber officinale* Roscoe towards anticancer activity was certified. Future evaluations can assess whether the combination of honey bee venom and ethanol extract of *Zingiber officinale* Roscoe may be more beneficial to impede the metastatic cancer or for remedy of established cancer.

261 **22 VI. Acknowledgement**Volume XVII Issue II Version I <sup>1 2 3</sup>**1**

| Treatment groups | Tumour volume (mL) |
|------------------|--------------------|
| EAC              | 8.29± 0.16         |
| Cisplatin        | 1.13 ± 0.31 r      |
| F 1              | 3.77 ± 0.35 r,z    |
| F 2              | 3.46 ± 0.46 r,z    |
| F 3              | 3.15 ± 0.75 r,z    |

Values are mean ± S.E.M. (n=6). P values: r < 0.001, as compared with EAC control. z < 0.001, as compared to cisplatin as standard (by one way ANOVA followed by Dunnett's multiple comparison test)

Figure 1: Table 1 :

**2**

Year 2017

Figure 2: Table 2 :

**3**

| Treatment groups | MST (Days)       | %ILS  |
|------------------|------------------|-------|
| EAC              | 15.20 ± 0.51     | -     |
| Cisplatin        | 25.34 ± 0.38 a   | 66.71 |
| F 1              | 19.65 ± 0.71 b   | 29.27 |
| F 2              | 22.93 ± 0.35 a,b | 50.85 |
| F 3              | 23.77 ± 0.40 a,b | 56.38 |

[Note: Values are mean ± S.E.M. (n=6). P values: a < 0.05, as compared with EAC control, b < 0.05, as compared to cisplatin as standard (by one way ANOVA followed by Dunnett's multiple comparison test) iv. Effect of combination of honey bee venom and ethanol extract of Zingiber officinale Roscoe on hematological parameters in DLA/ EAC tumour bearing mice Table]

Figure 3: Table 3 :

262

---

<sup>1</sup>© 2017 Global Journals Inc. (US)<sup>2</sup>Volume XVII Issue II Version I © 2017 Global Journals Inc. (US) Year 2017<sup>3</sup>In Vitro Cytotoxic Screening of Combination of Honey Bee Venom and Ethanol Extract of Zingiberaceae and in Vivo Anticancer Evaluation of them against DLA and EAC Bearing Mice

---

4

| Treatment groups | RBC count (x 10 <sup>9</sup> /mL) | WBC count(x10 <sup>4</sup> /mm <sup>3</sup> ) | Hb (g%)        |
|------------------|-----------------------------------|-----------------------------------------------|----------------|
| NORMAL           | 4.81± 0.13                        | 8.09± 0.10                                    | 14.78± 0.39    |
| DLA              | 3.11± 0.6 c                       | 19.78± 0.55 c                                 | 10.06± 0.42 c  |
| Cisplatin        | 3.75±0.25 r                       | 9.13± 0.23 r                                  | 13.87± 0.45 br |
| F 1              | 3.27± 0.20 cq                     | 17.06± 0.52 crz                               | 11.88± 0.17 cx |
| F 2              | 3.49± 0.52 cq                     | 15.58± 0.69 bry                               | 12.53± 0.01 c  |
| F 3              | 3.66± 0.30 cq                     | 11.52± 0.73 r                                 | 13.01± 4.10 cq |

[Note: n = 6, Values are mean ±S.E.M, one way ANOVA followed by Dunnet's multiple comparison test. p values: b< 0.01, c< 0.001, compared to the normal group; q< 0.01, r<0.001, as compared with EAC control; x< 0.05, y< 0.01, z< 0.001, as compared cisplatin treated group.]

Figure 4: Table 4 :





---

263 The authors are grateful to SR biotechnology laboratory, Jakkur, Bangalore-560065, Karnataka, India, for  
 264 technical support this investigation.

265 [Jain ()] , A K Jain . *Manual of Practical Physiology for MBBS* 2005. Arya Publications.

266 [Radhakrishnan et al. ()] , E K Radhakrishnan , S V Bava , S S Narayanan , L R Nath , A K Thulasidasan , E  
 267 V Soniya , R J Anto . 2014.

268 [Meyer et al. ()] 'A conventional general bioassay for active plant constituents'. B N Meyer , N R Ferrigni , J E  
 269 Putnam , L B Jacobsen , D E Nichols , J L McLaughlin . *Planta Med* 1982. 45 p. .

270 [Durairaj et al. ()] 'Antineoplastic and antioxidant activities of *Oxystelma esculentum* on swiss albino mice  
 271 bearing ehrlich ascites carcinoma'. A K Durairaj , T S Vaiyapuri , U P Mazumder , M Gupta . *Pharm*  
 272 *Biol* 2009. 47 (3) p. .

273 [Jemal et al. ()] 'Cancer statistics'. A Jemal , R Siegel , E Ward , T Murray , J Xu , M J Thun . *CA Cancer J*  
 274 *Clin* 2007. 57 (1) p. .

275 [Balachandran and Govindarajan ()] 'Canceran ayurveda perspective'. P Balachandran , R Govindarajan .  
 276 *Pharmacol Res* 2005. 51 (1) p. .

277 [Mondal et al. (2014)] 'Conventional chemotherapy: problems and scope for combined therapies with certain  
 278 herbal products and dietary supplements'. J Mondal , Panigrahi Ak , Khuda Bukhsh , AR . *Austain J Mol*  
 279 *Cell Biol* 2014. 19 August 2016. 1 (1) p. .

280 [Orsolic et al. ()] 'Direct antitumor activity of honey bee venom invivo and invitro'. N Orsolic , P Josipovic , I  
 281 Basic . *Egy J Nat Toxins* 2009. 6 (1) p. .

282 [Poltronieri et al. ()] 'Gingerol as a cancer chemopreventive agent: a review of its activity on different steps of  
 283 the metastatic process'. J Poltronieri , A B Becceneri , A M Fuzer , J C Filho , A C Martin , P C Vieira , N  
 284 Pouliot , M R Cominetti . *Mini Rev Med Chem* 2014. 14 (4) p. .

285 [Gingerol induces caspase-dependent apoptosis and prevents PMA-induced proliferation in colon cancer cells by inhibiting MAPK  
 286 'Gingerol induces caspase-dependent apoptosis and prevents PMA-induced proliferation in colon cancer cells  
 287 by inhibiting MAPK/AP-1 signaling'. *Plos one* 9 (8) p. .

288 [Kim et al. ()] 'Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-KB  
 289 in phorbol ester-stimulated mouse skin'. S O Kim , J K Kundu , Y K Shin , J H Park , M H Cho , T Y Kim  
 290 , Y J Surh . *Oncogene* 2005. 24 (6) p. .

291 [Lopez et al. ()] 'Global and regional burden of disease and risk factors, 2001: systematic analysis of population  
 292 health data'. A D Lopez , C D Mathers , M Ezzati , Jamison Dt , C J Murray . *Lancet* 2006. 367 (9524) p. .

293 [Ferlay et al. (2008)] *Global cancer facts and figures*, J Ferlay , H R Shin , F Bray , D Forman , C D Mather ,  
 294 D Parkin . [http://oralcancerfoundation.org/wp-content/uploads/2016/03/acspc-027766.](http://oralcancerfoundation.org/wp-content/uploads/2016/03/acspc-027766.pdf)  
 295 [pdf](http://oralcancerfoundation.org/wp-content/uploads/2016/03/acspc-027766.pdf) 2008. 08 May 2016. 2. (USA: American cancer society)

296 [Saluja et al. ()] 'In-vitro cytotoxic activity of leaves of *Madhuca longifolia* against Ehrlich Ascites carcinoma  
 297 (EAC) cell lines'. M S Saluja , B Sangameswaran , I S Hura , S Ajay , S K Gupta , M Chaturvedi . *IJDDHR*  
 298 2011. 1 (2) p. . (Suppl)

299 [Ames et al. ()] 'Oxidants, antioxidants, and the degenerative diseases of aging'. B N Ames , M K Shigenaga , T  
 300 M Hagen . *Proc Natl Acad Sci* 1993. 90 p. .

301 [Lai et al. ()] 'Piperine suppresses tumor growth and metastasis invitro and invivo in a 4T1 murine breast cancer  
 302 model'. L H Lai , Q H Fu , Y Liu , K Jiang , Q M Guo , Q Y Chen , B Yan , Wang Qq , Shen Jg . *Acta*  
 303 *Pharmacol Sin* 2012. 33 p. .

304 [Dai and Mumper ()] 'Plant phenolic: Extraction, Analysis and their antioxidant and anticancer properties'. J  
 305 Dai , R J Mumper . *Molecules* 2010. 15 p. .

306 [Sharma and Sharma ()] *Principles of pharmacology*, H L Sharma , K K Sharma . 2007. New Delhi: Paras  
 307 Medical Publisher.

308 [Orellana and Kasinski ()] 'Sulforhodamine B (SRB) assay in cell culture to investigate cell proliferation'. E A  
 309 Orellana , A L Kasinski . *Bio Protoc* 2016. 6 (21) p. .

310 [Shi et al. ()] 'Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing  
 311 apoptosis'. Y Shi , R P Sahu , S K Srivastava . *BMC Cancer* 2008. 8 p. 294.